Cohance Lifesciences Limited operates as a bio-pharmaceutical company that develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research…
Analysis
Hope premium
Cohance Lifesciences Limited carries what we call a hope premium: an average business trading at an ambitious price.
The price is expensive. You pay 101.5× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 28% yearly growth; analysts expect 12%. The market is pricing in far more than analysts expect: heroic expectations.
The trajectory is moderate and the balance sheet is sturdy. The company scores 10/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202323
6
2023202420252026
All-time high
69
Jan 2025
All-time low
6
Jun 2026
Average rank
37
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
36
7
1
6
Price/Earnings
3
7
31
43
Price/Book
41
10
19
28
Dividend Yield
1
1
1
23
Value (overall)
3
1
3
15
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.